TY - JOUR
T1 - Diabetic cardiomyopathy and metabolic remodeling of the heart
AU - Battiprolu, Pavan K.
AU - Lopez-Crisosto, Camila
AU - Wang, Zhao V.
AU - Nemchenko, Andriy
AU - Lavandero, Sergio
AU - Hill, Joseph A.
N1 - Funding Information:
This work was supported by grants from the NIH ( HL-075173 , J.A.H.; HL-080144 , J.A.H.; HL-090842 , J.A.H.), AHA ( 0640084N , J.A.H.; 12POST9030041 , P.K.B.), ADA mentor-based postdoctoral fellowship ( 7-08-MN-21-ADA , J.A.H. and P.K.B.), the AHA-Jon Holden DeHaan Foundation ( 0970518N , J.A.H.), and the Fondo Nacional de Desarrollo Cientifico y Tecnologico : FONDECYT 1120212 and ACT1111 (S.L.). C.L.C. is a recipient of a CONICYT fellowship , Chile.
PY - 2013
Y1 - 2013
N2 - The incidence and prevalence of diabetes mellitus are both increasing rapidly in societies around the globe. The majority of patients with diabetes succumb ultimately to heart disease, much of which stems from atherosclerotic disease and hypertension. However, the diabetic milieu is itself intrinsically noxious to the heart, and cardiomyopathy can develop independent of elevated blood pressure or coronary artery disease. This process, termed diabetic cardiomyopathy, is characterized by significant changes in the physiology, structure, and mechanical function of the heart. Presently, therapy for patients with diabetes focuses largely on glucose control, and attention to the heart commences with the onset of symptoms. When the latter develops, standard therapy for heart failure is applied. However, recent studies highlight that specific elements of the pathogenesis of diabetic heart disease are unique, raising the prospect of diabetes-specific therapeutic intervention. Here, we review recently unveiled insights into the pathogenesis of diabetic cardiomyopathy and associated metabolic remodeling with an eye toward identifying novel targets with therapeutic potential.
AB - The incidence and prevalence of diabetes mellitus are both increasing rapidly in societies around the globe. The majority of patients with diabetes succumb ultimately to heart disease, much of which stems from atherosclerotic disease and hypertension. However, the diabetic milieu is itself intrinsically noxious to the heart, and cardiomyopathy can develop independent of elevated blood pressure or coronary artery disease. This process, termed diabetic cardiomyopathy, is characterized by significant changes in the physiology, structure, and mechanical function of the heart. Presently, therapy for patients with diabetes focuses largely on glucose control, and attention to the heart commences with the onset of symptoms. When the latter develops, standard therapy for heart failure is applied. However, recent studies highlight that specific elements of the pathogenesis of diabetic heart disease are unique, raising the prospect of diabetes-specific therapeutic intervention. Here, we review recently unveiled insights into the pathogenesis of diabetic cardiomyopathy and associated metabolic remodeling with an eye toward identifying novel targets with therapeutic potential.
UR - http://www.scopus.com/inward/record.url?scp=84875232063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875232063&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2012.10.011
DO - 10.1016/j.lfs.2012.10.011
M3 - Review article
C2 - 23123443
AN - SCOPUS:84875232063
SN - 0024-3205
VL - 92
SP - 609
EP - 615
JO - Life Sciences
JF - Life Sciences
IS - 11
ER -